A vaccine to protect against infection with hepatitis C could be in use within 5 years, says Professor Sir Michael Houghton, who won the Nobel Prize for Medicine and Physiology along with three other scientists for discovering the hepatitis C virus (HCV) in 1989. Sir Michael will discuss the development of a vaccine in a special presentation at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held online this year. Up to 2 million new HCV infections occur every year around the world, with an estimated 70 million carriers of the virus globally, most of whom are not diagnosed. The virus is estimated to cause some 400,000 deaths annually. Many infected with the virus go on to develop liver cirrhosis and liver cancer. “While the advent of directly acting antivirals (DAAs) to cure hepatitis C has given us a huge weapon to turn the tide on this pandemic, there...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!




